-+ 0.00%
-+ 0.00%
-+ 0.00%
Did Alnylam Pharmaceuticals' 64% Drop Catch You Out? What Bears Saw
Share
Listen to the news

If you had been weighing Alnylam Pharmaceuticals against other biotech ideas in November 2025 and decided to hold on, the outcome would have been painful. Holding Alnylam Pharmaceuticals over the past year would have meant a 64.2% loss, including dividends. With that decline now on the table, the real puzzle is which assumptions about RNAi growth, TTR concentration risk, and pricing pressure were already visible then and worth more scrutiny.

Alnylam Pharmaceuticals has already moved. Pinpoint other ways to investigate the theme among 38 healthcare AI stocks.

The Argument You Would Have Been Weighing On Alnylam Pharmaceuticals

The shares cost US$454 at the start of the period. Anyone looking at Alnylam Pharmaceuticals then was choosing between two very different stories about RNA interference and rare disease drugs.

The bullish narrative saw a Fair Value of US$559, a price implied by assumptions of faster AMVUTTRA uptake and a structurally more profitable RNAi platform. That case leaned on rapid formulary access, a tripling prescriber base, and potential majority share in TTR therapies.

The bearish view pointed to a Fair Value of US$236, an implied price built on worries about TTR concentration risk and pricing pressure. Bears focused on expected mid single digit net price cuts for AMVUTTRA, rising royalties, and heavy R&D spending that might not translate into broad indications.

NasdaqGS:ALNY 1-Year Stock Price Chart
NasdaqGS:ALNY 1-Year Stock Price Chart

What The Evidence Around Alnylam Pharmaceuticals Actually Tested

The biggest new fact for Alnylam Pharmaceuticals was Q3 2026 results. Revenue reached US$1,458.1m and net income was US$2,167.3m, which lifted net margin to 148.6%. That supported the bullish profitability story, while the later cut to 2026 TTR guidance and law firm investigations around that reset backed the cautious view on growth quality. The evidence pointed in both directions.

The useful lesson is simple. When a drug platform is central to the pitch, track how guidance for that core franchise moves against reported revenue, profit and margin, and treat any reset as a separate line item from headline growth.

What You Would Be Paying For In Alnylam Pharmaceuticals Today

After a 64.2% decline over the past year, Alnylam Pharmaceuticals now trades at US$165. The analyst consensus Narrative on Simply Wall St sees its Fair Value as sitting above that level, based on the breadth of the RNAi pipeline and the TTR franchise.

Investors weighing that drop are really judging whether AMVUTTRA access and execution in wider cardiovascular and metabolic indications can support the RNAi story at this new price. For the fall to look like an opportunity rather than a warning, a buyer would need confidence that pivotal RNAi programs in prevalent diseases secure broad uptake.

"The broad RNAi portfolio at Alnylam Pharmaceuticals, with more than 25 programs across rare, specialty and prevalent conditions and multiple pivotal studies underway, creates repeated opportunities for new approvals that could add incremental revenue streams and help spread fixed R&D and SG&A over a larger sales base, which may support earnings."

One Narrative disagrees with today's price. → See where this Narrative says Alnylam Pharmaceuticals should trade

Go Straight To The Source

This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.

  • Company 1 - 48% below our estimate - sells accelerators and software that large cloud customers rely on for AI factory buildouts.
  • Company 2 - 44% below our estimate - supplies LED systems as sports venues and transport agencies switch to digital displays.
  • Company 3 - 42% below our estimate - expands lifestyle apparel platforms while reallocating capital from a divested label into brands.

That is three of the list. See all 35 potentially undervalued companies →

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending